Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT03914742
Title BGB-290 and Temozolomide in Treating Patients With Recurrent Gliomas With IDH1/2 Mutations
Recruitment Active, not recruiting
Gender both
Phase Phase Ib/II
Variant Requirements Yes
Sponsors Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Indications

high grade glioma

Therapies

Pamiparib + Temozolomide

Age Groups: adult | senior
Covered Countries USA

Facility Status City State Zip Country Details
UAB Comprehensive Cancer Center Birmingham Alabama 35294-3410 United States Details
University of California, Los Angeles Los Angeles California 90095 United States Details
Yale University New Haven Connecticut 06511 United States Details
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Baltimore Maryland 21231 United States Details
Dana Farber Cancer Institute Boston Massachusetts 02215 United States Details
Josephine Ford Cancer Center at Henry Ford Hospital Detroit Michigan 48202 United States Details
Washington University Saint Louis Missouri 63110 United States Details
Wake Forest University Comprehensive Cancer Center Winston-Salem North Carolina 27157-1096 United States Details
Cleveland Clinic Taussig Cancer Center Cleveland Ohio 44195 United States Details
University of Pennsylvania Philadelphia Pennsylvania 19104 United States Details
Hillman Cancer Center at University of Pittsburgh Cancer Institute Pittsburgh Pennsylvania 15232 United States Details
University of Virginia Charlottesville Virginia 22908 United States Details
*Shaded cells indicate that there was no data available from clincialtrials.gov for the field